Drugs / Visipaque 320
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | VISIPAQUE 270 | — | 1997-10-10 – 2017-04-05 | fda.gov ↗ |
| Approved | US (FDA) | VISIPAQUE 270 | — | 1996-03-22 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02171247 Comparator | Apr 2008 → Dec 2010 | — | Duke University | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visipaque 320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02171247 ↗ |